Epicgenetics New Collaboration with the University of Illinois

LOS ANGELES--(BUSINESS WIRE)--EpicGenetics, the world’s only laboratory to offer an objective, university medical center developed, award-winning, highly test sensitive and test specific diagnostic test for fibromyalgia, an immune deficiency medical disease known to affect nearly 1 out of every 15 people, has announced a collaboration with the University of Illinois College of Pharmacy to develop immune system modulating methods to address the immune system deficiencies and related medical pathways that have been documented as the diagnosable basis of fibromyalgia. Dr. Bruce Gillis and colleagues in the Department of Pathology at the University of Illinois College of Medicine at Chicago established and achieved peer-reviewed and published scientific principles which documented the “Unique Immunologic Patterns of Fibromyalgia" (as published in BMC Clinical Pathology) and which established this breakthrough diagnostic test for fibromyalgia, the FM/a® Test. EpicGenetics is now moving forward in completing necessary safety testing of these immune system modulating methods with the expectation that human trials will follow soon thereafter. The recruitment of volunteers with proven fibromyalgia as defined by the FM/a® Test, will serve as the basis of volunteer eligibility. There will be no pre-set limits on the number of volunteers who may be eligible to participate and they are encouraged to monitor the EpicGenetics Laboratory website (www.fmtest.com) in order to remain cognizant of these efforts and scientific pursuits. This intervention was developed to address the manifestations of fibromyalgia(FM). They are projected to be the first ever immune system-based pathway specific for this very serious and often incapacitating medical affliction.